Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: Results of a 6-week randomized study

International Clinical Psychopharmacology

Volumn 27, Issue 3, 2012, Pages 151-158

  Huang, Manli ^a   Luo, Benyan ^b   Hu, Jianbo ^a   Wei, Ning ^a   Chen, Lin ^a   Wang, Shanshan ^a   Zhou, Weihua ^a   Hu, Shaohua ^a   Xu, Yi ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

citalopram; disorders; Hamilton Anxiety Scale; paliperidone; somataform; Somatoform Disorders Screening Symptoms 7

Indexed keywords

CITALOPRAM; PALIPERIDONE;

ADULT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE OBSTRUCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SOMATOFORM DISORDER; SOMATOFORM DISORDERS SCREENING SYMPTOMS 7; SOMNOLENCE; SWEATING; TREATMENT EMERGENT SYMPTOM SCALE; VOMITING; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; CHINA; CITALOPRAM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PYRIMIDINES; SEROTONIN UPTAKE INHIBITORS; SOMATOFORM DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862791969     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328351c7e8     Document Type: Article

References (36)

1. Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, et al. (2005). Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Eur J Pain 9:33-38. (Pubitemid 40075397)
2. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr (2002). A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 112: 191-197.
3. Barsky AJ, Orav EJ, Bates DW (2005). Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 62:903-910. (Pubitemid 41126885)
4. Belous AR, Ramamoorthy S, Blakely RD, Factor MI, Dupin AM, Katasonov AB, et al. (2001). The state of the serotonin transporter protein in the platelets of patients with somatoform [correction of somatiform] disorders. Neurosci Behav Physiol 31:185-189. (Pubitemid 32492401)
5. De Waal MW, Arnold IA, Eekhof JA, van Hemert AM (2004). Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry 184: 470-476. (Pubitemid 38725705)
6. Dremencov E, El Mansari M, Blier P (2007). Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl) 194:63-72. (Pubitemid 47282734)
7. Fallon BA, Liebowitz MR, Salman E, Schneier FR, Jusino C, Hollander E, et al. (1993). Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol 13:438-441. (Pubitemid 24026106)
8. Ferreri M, Florent C, Gerard D (2000). [Sulpiride: study of 669 patient presenting with pain of psychological origin]. Encephale 26:58-66.
9. Fink P, Hansen MS, Oxhoj ML (2004). The prevalence of somatoform disorders among internal medical inpatients. J Psychosom Res 56: 413-418. (Pubitemid 38490729)
10. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
11. Han C, Pae CU, Lee BH, Ko YH, Masand PS, Patkar AA, et al. (2008). Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial. Prog Neuropsychopharmacol Biol Psychiatry 32:437-444. (Pubitemid 351178961)
12. Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J,Wong C, et al. (1999). Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 56:1033-1039. (Pubitemid 29526387)
13. Jacobi F, Wittchen HU, Holting C, Hofler M, Pfister H, Muller N, et al. (2004). Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 34:597-611. (Pubitemid 38735455)
14. Kroenke K, Mangelsdorff AD (1989). Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. Am J Med 86: 262-266. (Pubitemid 19081465)
15. Kroenke K, Spitzer RL, deGruy FV III, Hahn SR, Linzer M, Williams JB, et al. (1997). Multisomatoform disorder. An alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. Arch Gen Psychiatry 54:352-358. (Pubitemid 27171921)
16. Lee RA, West RM, Wilson JD (2005). The response to sertraline in men with chronic pelvic pain syndrome. Sex Transm Infect 81:147-149. (Pubitemid 40523827)
17. Leysen JE, Janssen PM, Megens AA, Schotte A (1994). Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 55 (Suppl):5-12. (Pubitemid 24179363)
18. Luo YL, Zhang MY, Wu WY, Li CB, Lu Z, Li QW (2009). A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder. Prog Neuropsychopharmacol Biol Psychiatry 33:1522-1525.
19. Nelson JC, Papakostas GI (2009). Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980-991.
20. Noyes R Jr., Happel RL, Muller BA, Holt CS, Kathol RG, Sieren LR, et al. (1998). Fluvoxamine for somatoform disorders: an open trial. Gen Hosp Psychiatry 20:339-344. (Pubitemid 28551184)
21. Nussbaum AM, Stroup TS (2008). Paliperidone for treatment of schizophrenia. Schizophr Bull 34:419-422.
22. Papakostas GI, Petersen TJ, Kinrys G, Burns AM,Worthington JJ, Alpert JE, et al. (2005). Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 66: 1326-1330. (Pubitemid 41546514)
23. Patkar AA, Masand PS, Krulewicz S, Mannelli P, Peindl K, Beebe KL, et al. (2007). A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med 120:448-454. (Pubitemid 46656247)
24. Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB (1996). Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol 11:247-254. (Pubitemid 27049289)
25. Phillips KA, Albertini RS, Rasmussen SA (2002). A randomized placebocontrolled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 59:381-388. (Pubitemid 34275257)
26. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, et al. (2006). Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31: 2505-2513. (Pubitemid 44607069)
27. Richelson E, Souder T (2000). Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68: 29-39.
28. Rief W, Hiller W (2003). A new approach to the assessment of the treatment effects of somatoform disorders. Psychosomatics 44:492-498. (Pubitemid 37352227)
29. Rief W, Hessel A, Braehler E (2001). Somatization symptoms and hypochondriacal features in the general population. Psychosom Med 63: 595-602. (Pubitemid 32695140)
30. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73. (Pubitemid 26112775)
31. Sicras-Mainar A, Navarro-Artieda R, Blanca-Tamayo M, Gimeno-de la Fuente V, Salvatella-Pasant J (2010). Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences. Curr Med Res Opin 26:2757-2764.
32. Silverstein B, Patel P (2011). Poor response to antidepressant medication of patients with depression accompanied by somatic symptomatology in the STAR*D Study. Psychiatry Res 187:121-124.
33. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28-40. (Pubitemid 43050100)
34. Turkington D, Grant JB, Ferrier IN, Rao NS, Linsley KR, Young AH (2002). A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. J Clin Psychiatry 63:778-781.
35. Volz HP, Moller HJ, Reimann I, Stoll KD (2000). Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial. Eur Neuropsychopharmacol 10:211-217. (Pubitemid 30227622)
36. Volz HP, Murck H, Kasper S, Moller HJ (2002). St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 164:294-300. (Pubitemid 35340996)